Innovate Biopharmaceuticals Inc (NASDAQ:INNT) shares saw unusually-high trading volume on Monday . Approximately 5,369,135 shares traded hands during trading, an increase of 1,434% from the previous session’s volume of 349,945 shares.The stock last traded at $2.48 and had previously closed at $2.14.

A number of hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in Innovate Biopharmaceuticals by 47.2% during the 4th quarter. Rhumbline Advisers now owns 23,372 shares of the company’s stock valued at $54,000 after purchasing an additional 7,490 shares in the last quarter. Dynasty Wealth Management LLC increased its holdings in Innovate Biopharmaceuticals by 110.8% during the 3rd quarter. Dynasty Wealth Management LLC now owns 35,570 shares of the company’s stock valued at $243,000 after purchasing an additional 18,696 shares in the last quarter. Bank of Montreal Can increased its holdings in Innovate Biopharmaceuticals by 15,264.9% during the 3rd quarter. Bank of Montreal Can now owns 20,128 shares of the company’s stock valued at $138,000 after purchasing an additional 19,997 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Innovate Biopharmaceuticals during the 3rd quarter valued at $150,000. Finally, Northern Trust Corp acquired a new stake in Innovate Biopharmaceuticals during the 2nd quarter valued at $530,000. 12.26% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Innovate Biopharmaceuticals (INNT) Sees Large Volume Increase” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/innovate-biopharmaceuticals-innt-sees-large-volume-increase/2900333.html.

About Innovate Biopharmaceuticals (NASDAQ:INNT)

Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease.

Recommended Story: Understanding the different types of bonds

Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.